What series of products are available in Nanjing?

Nanjing Egg Bio-Technology Co., Ltd. was founded in March 2002, is a new type of Sino-foreign joint venture biotechnology company, with diagnostic reagents and medical devices as the main support industry. The company is located in Nanjing Zhongshan Science and Technology Park, covering an area of more than 40 acres, with a total construction area of more than 17,000 square meters, with first-class production facilities and equipment, according to the national standards for the construction of the GMP plant of more than 1,000 square meters. At present, the company has nearly 20 national patents, in May 2011, the company successfully passed the TUV Rheinland ISO13485 quality management system certification and CE certification, so far, the base of the egg biological has developed into a set of professional research and development, production and sales in one of the modern high-tech enterprises.

We own the brand of "Egg Bio", and our products mainly cover cardiovascular, cerebrovascular, oncology, renal, infectious diseases and other disease areas, with market-leading cardiovascular series of marker test kits and immunoquantitative analyzers, and set up a bedside rapid diagnostic engineering and technology center in 2011, which has several technical platforms to carry out bedside rapid diagnostics. In 2011, the company set up a bedside rapid diagnosis engineering technology center with several technology platforms, which can carry out research on bedside rapid diagnosis instruments and reagents. Meanwhile, the company has also independently established a high-level genetic engineering and antibody engineering platform, which is capable of conducting research on antibody drugs.

The company adopts the management strategy of focusing on the development of new products while expanding the production scale of original products and market share. In China, the company has an extensive distribution network and specialized marketing team, with nearly 200 sales staff and nearly 50 strategic partners, more than 200 distributors, and more than 800 Chinese hospital users, forming a nationwide sales network. Meanwhile, the company's series of products are exported to Europe, America, Asia and Africa. In the future, EggBio will grasp new opportunities and meet new challenges, aiming to become a biotechnology company with international competitiveness, insisting on independent innovation as the inexhaustible driving force for the company's survival and development, and focusing on building clinical testing systems and antibody drugs with independent intellectual property rights and international advantages, contributing to China's biomedical industry and serving human health.